AZD5672 (increasing dose up to 150mg) + digoxin (single dose on day 12)

Drug: AZD5672

50 mg, for 13 days

Drug: Digoxin

0.5mg dose

Other Name: Lanoxin

Eligibility

Ages Eligible for Study:

18 Years to 50 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Provision of signed written informed consent.

Females should not be of childbearing potential

Clinically normal physical and laboratory findings as judged by the investigator, including negative drug test and negative tests of Hepatitis B surface antigen, antibodies to Hepatitis C virus and antibodies to HIV.

Exclusion Criteria:

Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate

Known allergy to digoxin or previous complications to digoxin therapy.

Participation in any clinical study involving an investigational product in the 3 months prior to enrolment.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00723424